Global Hadron Therapy
Global Hadron Therapy

Hadron Therapy Comprehensive Study by Type (Electron Beam, Neutron Beam, Alpha Particle Beam, Proton Beam, Carbon Ion Beam, Beta Particle Beam), Application (Treatment Applications, Research Applications), Cancer Type (Pediatric Cancer, Bone and Soft Tissue Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Eye Cancer, Head & Neck Cancer, Others), End User (Hospitals, Cancer Research Centers, Clinics) Players and Region - Global Market Outlook to 2024

Hadron Therapy Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 246 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Hadron Therapy Market Scope
Technological advancements including reduced contrary effects and less radiation dose transmitted to healthy tissues during the radiation procedure will help to boost global Hadron therapy market in the forecasted period. Hardon therapy is also known as ion beam therapy or particle beam therapy. Hardon therapy is a type of therapy used ionizing radiation for cancer treatment. This therapy destroys the cancerous cells by damaging their DNA. The exclusive property of hadron therapy is physical and radiobiological properties of particles, which permit them to penetrate the tissues with less diffusion and transfer supreme energy within a specific area.

The market study is being classified by Type (Electron Beam, Neutron Beam, Alpha Particle Beam, Proton Beam, Carbon Ion Beam and Beta Particle Beam), by Application (Treatment Applications and Research Applications) and major geographies with country level break-up.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hadron Therapy market throughout the predicted period.

Koninklijke Philips N.V. (Netherlands), Ion Beam Applications SA (Belgium), Advanced Oncotherapy (United Kingdom), Hitachi, Ltd. (Japan), Varian Medical Systems, Inc. (United States), Optivus Proton Therapy, Inc. (United States), Mevion Medical Systems (United States), ProTom International (United States), Mitsubishi Electric Corporation (Japan) and Sumitomo Corporation (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ProNova Solutions, LLC (United States), Provision Healthcare (United States) and Danfysik A/S (Denmark).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Hadron Therapy market by Type, Application and Region.

On the basis of geography, the market of Hadron Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Cancer Type, the sub-segment i.e. Pediatric Cancer will boost the Hadron Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Hadron Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 25th April 2019, Royal Philips a global leader in health technology has launched IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, increase efficiency and allow operational superiority in radiotherapy departments.
On 7th March 2019, Royal Philips), a global leader in health technology has acquired the Healthcare Information Systems business of Carestream Health Inc., a United States-based provider of medical imaging and healthcare IT solutions for hospitals, imaging centers, and specialty medical clinics.


Market Trend
  • Growing Access to Medical Insurance
  • Technological Advancements in Cancer Treatment Therapies

Market Drivers
  • Increase in Prevalence’s Of Cancer
  • Upsurge in Healthcare Disbursement

Opportunities
  • Huge Opportunity in Emerging Countries
  • Growing Healthcare Expenditure in Developing Nations

Restraints
  • Dearth of Awareness about Hadron Therapy
  • Less Number of Treatment Providers

Challenges
  • High Product Developmental Cost


Key Target Audience
Therapy Providers, Medical Research and Development Institutes and Associations, Potential Investors, Government Bodies, Government and Private Research Center and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Electron Beam
  • Neutron Beam
  • Alpha Particle Beam
  • Proton Beam
  • Carbon Ion Beam
  • Beta Particle Beam
By Application
  • Treatment Applications
  • Research Applications
By Cancer Type
  • Pediatric Cancer
  • Bone and Soft Tissue Cancer
  • Prostate Cancer
  • Lung Cancer
  • Liver Cancer
  • Eye Cancer
  • Head & Neck Cancer
  • Others

By End User
  • Hospitals
  • Cancer Research Centers
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Prevalence’s Of Cancer
      • 3.2.2. Upsurge in Healthcare Disbursement
    • 3.3. Market Challenges
      • 3.3.1. High Product Developmental Cost
    • 3.4. Market Trends
      • 3.4.1. Growing Access to Medical Insurance
      • 3.4.2. Technological Advancements in Cancer Treatment Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hadron Therapy, by Type, Application, Cancer Type, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Hadron Therapy (Value)
      • 5.2.1. Global Hadron Therapy by: Type (Value)
        • 5.2.1.1. Electron Beam
        • 5.2.1.2. Neutron Beam
        • 5.2.1.3. Alpha Particle Beam
        • 5.2.1.4. Proton Beam
        • 5.2.1.5. Carbon Ion Beam
        • 5.2.1.6. Beta Particle Beam
      • 5.2.2. Global Hadron Therapy by: Application (Value)
        • 5.2.2.1. Treatment Applications
        • 5.2.2.2. Research Applications
      • 5.2.3. Global Hadron Therapy by: Cancer Type (Value)
        • 5.2.3.1. Pediatric Cancer
        • 5.2.3.2. Bone and Soft Tissue Cancer
        • 5.2.3.3. Prostate Cancer
        • 5.2.3.4. Lung Cancer
        • 5.2.3.5. Liver Cancer
        • 5.2.3.6. Eye Cancer
        • 5.2.3.7. Head & Neck Cancer
        • 5.2.3.8. Others
      • 5.2.4. Global Hadron Therapy by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Cancer Research Centers
        • 5.2.4.3. Clinics
      • 5.2.5. Global Hadron Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hadron Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Koninklijke Philips N.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ion Beam Applications SA (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Advanced Oncotherapy (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hitachi, Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Varian Medical Systems, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Optivus Proton Therapy, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mevion Medical Systems (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ProTom International (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mitsubishi Electric Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sumitomo Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hadron Therapy Sale, by Type, Application, Cancer Type, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Hadron Therapy (Value)
      • 7.2.1. Global Hadron Therapy by: Type (Value)
        • 7.2.1.1. Electron Beam
        • 7.2.1.2. Neutron Beam
        • 7.2.1.3. Alpha Particle Beam
        • 7.2.1.4. Proton Beam
        • 7.2.1.5. Carbon Ion Beam
        • 7.2.1.6. Beta Particle Beam
      • 7.2.2. Global Hadron Therapy by: Application (Value)
        • 7.2.2.1. Treatment Applications
        • 7.2.2.2. Research Applications
      • 7.2.3. Global Hadron Therapy by: Cancer Type (Value)
        • 7.2.3.1. Pediatric Cancer
        • 7.2.3.2. Bone and Soft Tissue Cancer
        • 7.2.3.3. Prostate Cancer
        • 7.2.3.4. Lung Cancer
        • 7.2.3.5. Liver Cancer
        • 7.2.3.6. Eye Cancer
        • 7.2.3.7. Head & Neck Cancer
        • 7.2.3.8. Others
      • 7.2.4. Global Hadron Therapy by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Cancer Research Centers
        • 7.2.4.3. Clinics
      • 7.2.5. Global Hadron Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hadron Therapy: by Type(USD Million)
  • Table 2. Hadron Therapy Electron Beam , by Region USD Million (2013-2018)
  • Table 3. Hadron Therapy Neutron Beam , by Region USD Million (2013-2018)
  • Table 4. Hadron Therapy Alpha Particle Beam , by Region USD Million (2013-2018)
  • Table 5. Hadron Therapy Proton Beam , by Region USD Million (2013-2018)
  • Table 6. Hadron Therapy Carbon Ion Beam , by Region USD Million (2013-2018)
  • Table 7. Hadron Therapy Beta Particle Beam , by Region USD Million (2013-2018)
  • Table 8. Hadron Therapy: by Application(USD Million)
  • Table 9. Hadron Therapy Treatment Applications , by Region USD Million (2013-2018)
  • Table 10. Hadron Therapy Research Applications , by Region USD Million (2013-2018)
  • Table 11. Hadron Therapy: by Cancer Type(USD Million)
  • Table 12. Hadron Therapy Pediatric Cancer , by Region USD Million (2013-2018)
  • Table 13. Hadron Therapy Bone and Soft Tissue Cancer , by Region USD Million (2013-2018)
  • Table 14. Hadron Therapy Prostate Cancer , by Region USD Million (2013-2018)
  • Table 15. Hadron Therapy Lung Cancer , by Region USD Million (2013-2018)
  • Table 16. Hadron Therapy Liver Cancer , by Region USD Million (2013-2018)
  • Table 17. Hadron Therapy Eye Cancer , by Region USD Million (2013-2018)
  • Table 18. Hadron Therapy Head & Neck Cancer , by Region USD Million (2013-2018)
  • Table 19. Hadron Therapy Others , by Region USD Million (2013-2018)
  • Table 20. Hadron Therapy: by End User(USD Million)
  • Table 21. Hadron Therapy Hospitals , by Region USD Million (2013-2018)
  • Table 22. Hadron Therapy Cancer Research Centers , by Region USD Million (2013-2018)
  • Table 23. Hadron Therapy Clinics , by Region USD Million (2013-2018)
  • Table 24. South America Hadron Therapy, by Country USD Million (2013-2018)
  • Table 25. South America Hadron Therapy, by Type USD Million (2013-2018)
  • Table 26. South America Hadron Therapy, by Application USD Million (2013-2018)
  • Table 27. South America Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 28. South America Hadron Therapy, by End User USD Million (2013-2018)
  • Table 29. Brazil Hadron Therapy, by Type USD Million (2013-2018)
  • Table 30. Brazil Hadron Therapy, by Application USD Million (2013-2018)
  • Table 31. Brazil Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 32. Brazil Hadron Therapy, by End User USD Million (2013-2018)
  • Table 33. Argentina Hadron Therapy, by Type USD Million (2013-2018)
  • Table 34. Argentina Hadron Therapy, by Application USD Million (2013-2018)
  • Table 35. Argentina Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 36. Argentina Hadron Therapy, by End User USD Million (2013-2018)
  • Table 37. Rest of South America Hadron Therapy, by Type USD Million (2013-2018)
  • Table 38. Rest of South America Hadron Therapy, by Application USD Million (2013-2018)
  • Table 39. Rest of South America Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 40. Rest of South America Hadron Therapy, by End User USD Million (2013-2018)
  • Table 41. Asia Pacific Hadron Therapy, by Country USD Million (2013-2018)
  • Table 42. Asia Pacific Hadron Therapy, by Type USD Million (2013-2018)
  • Table 43. Asia Pacific Hadron Therapy, by Application USD Million (2013-2018)
  • Table 44. Asia Pacific Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 45. Asia Pacific Hadron Therapy, by End User USD Million (2013-2018)
  • Table 46. China Hadron Therapy, by Type USD Million (2013-2018)
  • Table 47. China Hadron Therapy, by Application USD Million (2013-2018)
  • Table 48. China Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 49. China Hadron Therapy, by End User USD Million (2013-2018)
  • Table 50. Japan Hadron Therapy, by Type USD Million (2013-2018)
  • Table 51. Japan Hadron Therapy, by Application USD Million (2013-2018)
  • Table 52. Japan Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 53. Japan Hadron Therapy, by End User USD Million (2013-2018)
  • Table 54. India Hadron Therapy, by Type USD Million (2013-2018)
  • Table 55. India Hadron Therapy, by Application USD Million (2013-2018)
  • Table 56. India Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 57. India Hadron Therapy, by End User USD Million (2013-2018)
  • Table 58. South Korea Hadron Therapy, by Type USD Million (2013-2018)
  • Table 59. South Korea Hadron Therapy, by Application USD Million (2013-2018)
  • Table 60. South Korea Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 61. South Korea Hadron Therapy, by End User USD Million (2013-2018)
  • Table 62. Taiwan Hadron Therapy, by Type USD Million (2013-2018)
  • Table 63. Taiwan Hadron Therapy, by Application USD Million (2013-2018)
  • Table 64. Taiwan Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 65. Taiwan Hadron Therapy, by End User USD Million (2013-2018)
  • Table 66. Australia Hadron Therapy, by Type USD Million (2013-2018)
  • Table 67. Australia Hadron Therapy, by Application USD Million (2013-2018)
  • Table 68. Australia Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 69. Australia Hadron Therapy, by End User USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Hadron Therapy, by Type USD Million (2013-2018)
  • Table 71. Rest of Asia-Pacific Hadron Therapy, by Application USD Million (2013-2018)
  • Table 72. Rest of Asia-Pacific Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 73. Rest of Asia-Pacific Hadron Therapy, by End User USD Million (2013-2018)
  • Table 74. Europe Hadron Therapy, by Country USD Million (2013-2018)
  • Table 75. Europe Hadron Therapy, by Type USD Million (2013-2018)
  • Table 76. Europe Hadron Therapy, by Application USD Million (2013-2018)
  • Table 77. Europe Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 78. Europe Hadron Therapy, by End User USD Million (2013-2018)
  • Table 79. Germany Hadron Therapy, by Type USD Million (2013-2018)
  • Table 80. Germany Hadron Therapy, by Application USD Million (2013-2018)
  • Table 81. Germany Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 82. Germany Hadron Therapy, by End User USD Million (2013-2018)
  • Table 83. France Hadron Therapy, by Type USD Million (2013-2018)
  • Table 84. France Hadron Therapy, by Application USD Million (2013-2018)
  • Table 85. France Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 86. France Hadron Therapy, by End User USD Million (2013-2018)
  • Table 87. Italy Hadron Therapy, by Type USD Million (2013-2018)
  • Table 88. Italy Hadron Therapy, by Application USD Million (2013-2018)
  • Table 89. Italy Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 90. Italy Hadron Therapy, by End User USD Million (2013-2018)
  • Table 91. United Kingdom Hadron Therapy, by Type USD Million (2013-2018)
  • Table 92. United Kingdom Hadron Therapy, by Application USD Million (2013-2018)
  • Table 93. United Kingdom Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 94. United Kingdom Hadron Therapy, by End User USD Million (2013-2018)
  • Table 95. Netherlands Hadron Therapy, by Type USD Million (2013-2018)
  • Table 96. Netherlands Hadron Therapy, by Application USD Million (2013-2018)
  • Table 97. Netherlands Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 98. Netherlands Hadron Therapy, by End User USD Million (2013-2018)
  • Table 99. Rest of Europe Hadron Therapy, by Type USD Million (2013-2018)
  • Table 100. Rest of Europe Hadron Therapy, by Application USD Million (2013-2018)
  • Table 101. Rest of Europe Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 102. Rest of Europe Hadron Therapy, by End User USD Million (2013-2018)
  • Table 103. MEA Hadron Therapy, by Country USD Million (2013-2018)
  • Table 104. MEA Hadron Therapy, by Type USD Million (2013-2018)
  • Table 105. MEA Hadron Therapy, by Application USD Million (2013-2018)
  • Table 106. MEA Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 107. MEA Hadron Therapy, by End User USD Million (2013-2018)
  • Table 108. Middle East Hadron Therapy, by Type USD Million (2013-2018)
  • Table 109. Middle East Hadron Therapy, by Application USD Million (2013-2018)
  • Table 110. Middle East Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 111. Middle East Hadron Therapy, by End User USD Million (2013-2018)
  • Table 112. Africa Hadron Therapy, by Type USD Million (2013-2018)
  • Table 113. Africa Hadron Therapy, by Application USD Million (2013-2018)
  • Table 114. Africa Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 115. Africa Hadron Therapy, by End User USD Million (2013-2018)
  • Table 116. North America Hadron Therapy, by Country USD Million (2013-2018)
  • Table 117. North America Hadron Therapy, by Type USD Million (2013-2018)
  • Table 118. North America Hadron Therapy, by Application USD Million (2013-2018)
  • Table 119. North America Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 120. North America Hadron Therapy, by End User USD Million (2013-2018)
  • Table 121. United States Hadron Therapy, by Type USD Million (2013-2018)
  • Table 122. United States Hadron Therapy, by Application USD Million (2013-2018)
  • Table 123. United States Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 124. United States Hadron Therapy, by End User USD Million (2013-2018)
  • Table 125. Canada Hadron Therapy, by Type USD Million (2013-2018)
  • Table 126. Canada Hadron Therapy, by Application USD Million (2013-2018)
  • Table 127. Canada Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 128. Canada Hadron Therapy, by End User USD Million (2013-2018)
  • Table 129. Mexico Hadron Therapy, by Type USD Million (2013-2018)
  • Table 130. Mexico Hadron Therapy, by Application USD Million (2013-2018)
  • Table 131. Mexico Hadron Therapy, by Cancer Type USD Million (2013-2018)
  • Table 132. Mexico Hadron Therapy, by End User USD Million (2013-2018)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Hadron Therapy: by Type(USD Million)
  • Table 144. Hadron Therapy Electron Beam , by Region USD Million (2019-2024)
  • Table 145. Hadron Therapy Neutron Beam , by Region USD Million (2019-2024)
  • Table 146. Hadron Therapy Alpha Particle Beam , by Region USD Million (2019-2024)
  • Table 147. Hadron Therapy Proton Beam , by Region USD Million (2019-2024)
  • Table 148. Hadron Therapy Carbon Ion Beam , by Region USD Million (2019-2024)
  • Table 149. Hadron Therapy Beta Particle Beam , by Region USD Million (2019-2024)
  • Table 150. Hadron Therapy: by Application(USD Million)
  • Table 151. Hadron Therapy Treatment Applications , by Region USD Million (2019-2024)
  • Table 152. Hadron Therapy Research Applications , by Region USD Million (2019-2024)
  • Table 153. Hadron Therapy: by Cancer Type(USD Million)
  • Table 154. Hadron Therapy Pediatric Cancer , by Region USD Million (2019-2024)
  • Table 155. Hadron Therapy Bone and Soft Tissue Cancer , by Region USD Million (2019-2024)
  • Table 156. Hadron Therapy Prostate Cancer , by Region USD Million (2019-2024)
  • Table 157. Hadron Therapy Lung Cancer , by Region USD Million (2019-2024)
  • Table 158. Hadron Therapy Liver Cancer , by Region USD Million (2019-2024)
  • Table 159. Hadron Therapy Eye Cancer , by Region USD Million (2019-2024)
  • Table 160. Hadron Therapy Head & Neck Cancer , by Region USD Million (2019-2024)
  • Table 161. Hadron Therapy Others , by Region USD Million (2019-2024)
  • Table 162. Hadron Therapy: by End User(USD Million)
  • Table 163. Hadron Therapy Hospitals , by Region USD Million (2019-2024)
  • Table 164. Hadron Therapy Cancer Research Centers , by Region USD Million (2019-2024)
  • Table 165. Hadron Therapy Clinics , by Region USD Million (2019-2024)
  • Table 166. South America Hadron Therapy, by Country USD Million (2019-2024)
  • Table 167. South America Hadron Therapy, by Type USD Million (2019-2024)
  • Table 168. South America Hadron Therapy, by Application USD Million (2019-2024)
  • Table 169. South America Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 170. South America Hadron Therapy, by End User USD Million (2019-2024)
  • Table 171. Brazil Hadron Therapy, by Type USD Million (2019-2024)
  • Table 172. Brazil Hadron Therapy, by Application USD Million (2019-2024)
  • Table 173. Brazil Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 174. Brazil Hadron Therapy, by End User USD Million (2019-2024)
  • Table 175. Argentina Hadron Therapy, by Type USD Million (2019-2024)
  • Table 176. Argentina Hadron Therapy, by Application USD Million (2019-2024)
  • Table 177. Argentina Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 178. Argentina Hadron Therapy, by End User USD Million (2019-2024)
  • Table 179. Rest of South America Hadron Therapy, by Type USD Million (2019-2024)
  • Table 180. Rest of South America Hadron Therapy, by Application USD Million (2019-2024)
  • Table 181. Rest of South America Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 182. Rest of South America Hadron Therapy, by End User USD Million (2019-2024)
  • Table 183. Asia Pacific Hadron Therapy, by Country USD Million (2019-2024)
  • Table 184. Asia Pacific Hadron Therapy, by Type USD Million (2019-2024)
  • Table 185. Asia Pacific Hadron Therapy, by Application USD Million (2019-2024)
  • Table 186. Asia Pacific Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 187. Asia Pacific Hadron Therapy, by End User USD Million (2019-2024)
  • Table 188. China Hadron Therapy, by Type USD Million (2019-2024)
  • Table 189. China Hadron Therapy, by Application USD Million (2019-2024)
  • Table 190. China Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 191. China Hadron Therapy, by End User USD Million (2019-2024)
  • Table 192. Japan Hadron Therapy, by Type USD Million (2019-2024)
  • Table 193. Japan Hadron Therapy, by Application USD Million (2019-2024)
  • Table 194. Japan Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 195. Japan Hadron Therapy, by End User USD Million (2019-2024)
  • Table 196. India Hadron Therapy, by Type USD Million (2019-2024)
  • Table 197. India Hadron Therapy, by Application USD Million (2019-2024)
  • Table 198. India Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 199. India Hadron Therapy, by End User USD Million (2019-2024)
  • Table 200. South Korea Hadron Therapy, by Type USD Million (2019-2024)
  • Table 201. South Korea Hadron Therapy, by Application USD Million (2019-2024)
  • Table 202. South Korea Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 203. South Korea Hadron Therapy, by End User USD Million (2019-2024)
  • Table 204. Taiwan Hadron Therapy, by Type USD Million (2019-2024)
  • Table 205. Taiwan Hadron Therapy, by Application USD Million (2019-2024)
  • Table 206. Taiwan Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 207. Taiwan Hadron Therapy, by End User USD Million (2019-2024)
  • Table 208. Australia Hadron Therapy, by Type USD Million (2019-2024)
  • Table 209. Australia Hadron Therapy, by Application USD Million (2019-2024)
  • Table 210. Australia Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 211. Australia Hadron Therapy, by End User USD Million (2019-2024)
  • Table 212. Rest of Asia-Pacific Hadron Therapy, by Type USD Million (2019-2024)
  • Table 213. Rest of Asia-Pacific Hadron Therapy, by Application USD Million (2019-2024)
  • Table 214. Rest of Asia-Pacific Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 215. Rest of Asia-Pacific Hadron Therapy, by End User USD Million (2019-2024)
  • Table 216. Europe Hadron Therapy, by Country USD Million (2019-2024)
  • Table 217. Europe Hadron Therapy, by Type USD Million (2019-2024)
  • Table 218. Europe Hadron Therapy, by Application USD Million (2019-2024)
  • Table 219. Europe Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 220. Europe Hadron Therapy, by End User USD Million (2019-2024)
  • Table 221. Germany Hadron Therapy, by Type USD Million (2019-2024)
  • Table 222. Germany Hadron Therapy, by Application USD Million (2019-2024)
  • Table 223. Germany Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 224. Germany Hadron Therapy, by End User USD Million (2019-2024)
  • Table 225. France Hadron Therapy, by Type USD Million (2019-2024)
  • Table 226. France Hadron Therapy, by Application USD Million (2019-2024)
  • Table 227. France Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 228. France Hadron Therapy, by End User USD Million (2019-2024)
  • Table 229. Italy Hadron Therapy, by Type USD Million (2019-2024)
  • Table 230. Italy Hadron Therapy, by Application USD Million (2019-2024)
  • Table 231. Italy Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 232. Italy Hadron Therapy, by End User USD Million (2019-2024)
  • Table 233. United Kingdom Hadron Therapy, by Type USD Million (2019-2024)
  • Table 234. United Kingdom Hadron Therapy, by Application USD Million (2019-2024)
  • Table 235. United Kingdom Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 236. United Kingdom Hadron Therapy, by End User USD Million (2019-2024)
  • Table 237. Netherlands Hadron Therapy, by Type USD Million (2019-2024)
  • Table 238. Netherlands Hadron Therapy, by Application USD Million (2019-2024)
  • Table 239. Netherlands Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 240. Netherlands Hadron Therapy, by End User USD Million (2019-2024)
  • Table 241. Rest of Europe Hadron Therapy, by Type USD Million (2019-2024)
  • Table 242. Rest of Europe Hadron Therapy, by Application USD Million (2019-2024)
  • Table 243. Rest of Europe Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 244. Rest of Europe Hadron Therapy, by End User USD Million (2019-2024)
  • Table 245. MEA Hadron Therapy, by Country USD Million (2019-2024)
  • Table 246. MEA Hadron Therapy, by Type USD Million (2019-2024)
  • Table 247. MEA Hadron Therapy, by Application USD Million (2019-2024)
  • Table 248. MEA Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 249. MEA Hadron Therapy, by End User USD Million (2019-2024)
  • Table 250. Middle East Hadron Therapy, by Type USD Million (2019-2024)
  • Table 251. Middle East Hadron Therapy, by Application USD Million (2019-2024)
  • Table 252. Middle East Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 253. Middle East Hadron Therapy, by End User USD Million (2019-2024)
  • Table 254. Africa Hadron Therapy, by Type USD Million (2019-2024)
  • Table 255. Africa Hadron Therapy, by Application USD Million (2019-2024)
  • Table 256. Africa Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 257. Africa Hadron Therapy, by End User USD Million (2019-2024)
  • Table 258. North America Hadron Therapy, by Country USD Million (2019-2024)
  • Table 259. North America Hadron Therapy, by Type USD Million (2019-2024)
  • Table 260. North America Hadron Therapy, by Application USD Million (2019-2024)
  • Table 261. North America Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 262. North America Hadron Therapy, by End User USD Million (2019-2024)
  • Table 263. United States Hadron Therapy, by Type USD Million (2019-2024)
  • Table 264. United States Hadron Therapy, by Application USD Million (2019-2024)
  • Table 265. United States Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 266. United States Hadron Therapy, by End User USD Million (2019-2024)
  • Table 267. Canada Hadron Therapy, by Type USD Million (2019-2024)
  • Table 268. Canada Hadron Therapy, by Application USD Million (2019-2024)
  • Table 269. Canada Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 270. Canada Hadron Therapy, by End User USD Million (2019-2024)
  • Table 271. Mexico Hadron Therapy, by Type USD Million (2019-2024)
  • Table 272. Mexico Hadron Therapy, by Application USD Million (2019-2024)
  • Table 273. Mexico Hadron Therapy, by Cancer Type USD Million (2019-2024)
  • Table 274. Mexico Hadron Therapy, by End User USD Million (2019-2024)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hadron Therapy: by Type USD Million (2013-2018)
  • Figure 5. Global Hadron Therapy: by Application USD Million (2013-2018)
  • Figure 6. Global Hadron Therapy: by Cancer Type USD Million (2013-2018)
  • Figure 7. Global Hadron Therapy: by End User USD Million (2013-2018)
  • Figure 8. South America Hadron Therapy Share (%), by Country
  • Figure 9. Asia Pacific Hadron Therapy Share (%), by Country
  • Figure 10. Europe Hadron Therapy Share (%), by Country
  • Figure 11. MEA Hadron Therapy Share (%), by Country
  • Figure 12. North America Hadron Therapy Share (%), by Country
  • Figure 13. Global Hadron Therapy share by Players 2018 (%)
  • Figure 14. Global Hadron Therapy share by Players (Top 3) 2018(%)
  • Figure 15. Global Hadron Therapy share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2018
  • Figure 19. Ion Beam Applications SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 20. Ion Beam Applications SA (Belgium) Revenue: by Geography 2018
  • Figure 21. Advanced Oncotherapy (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Advanced Oncotherapy (United Kingdom) Revenue: by Geography 2018
  • Figure 23. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Hitachi, Ltd. (Japan) Revenue: by Geography 2018
  • Figure 25. Varian Medical Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Varian Medical Systems, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Optivus Proton Therapy, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Optivus Proton Therapy, Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Mevion Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mevion Medical Systems (United States) Revenue: by Geography 2018
  • Figure 31. ProTom International (United States) Revenue, Net Income and Gross profit
  • Figure 32. ProTom International (United States) Revenue: by Geography 2018
  • Figure 33. Mitsubishi Electric Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Mitsubishi Electric Corporation (Japan) Revenue: by Geography 2018
  • Figure 35. Sumitomo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Sumitomo Corporation (Japan) Revenue: by Geography 2018
  • Figure 37. Global Hadron Therapy: by Type USD Million (2019-2024)
  • Figure 38. Global Hadron Therapy: by Application USD Million (2019-2024)
  • Figure 39. Global Hadron Therapy: by Cancer Type USD Million (2019-2024)
  • Figure 40. Global Hadron Therapy: by End User USD Million (2019-2024)
  • Figure 41. South America Hadron Therapy Share (%), by Country
  • Figure 42. Asia Pacific Hadron Therapy Share (%), by Country
  • Figure 43. Europe Hadron Therapy Share (%), by Country
  • Figure 44. MEA Hadron Therapy Share (%), by Country
  • Figure 45. North America Hadron Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Koninklijke Philips N.V. (Netherlands)
  • Ion Beam Applications SA (Belgium)
  • Advanced Oncotherapy (United Kingdom)
  • Hitachi, Ltd. (Japan)
  • Varian Medical Systems, Inc. (United States)
  • Optivus Proton Therapy, Inc. (United States)
  • Mevion Medical Systems (United States)
  • ProTom International (United States)
  • Mitsubishi Electric Corporation (Japan)
  • Sumitomo Corporation (Japan)
Additional players considered in the study are as follows:
ProNova Solutions, LLC (United States) , Provision Healthcare (United States) , Danfysik A/S (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation